Paul Stuka Acquires 10,000 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka acquired 10,000 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $1.19 per share, with a total value of $11,900.00. Following the transaction, the director owned 632,871 shares of the company’s stock, valued at approximately $753,116.49. The trade was a 1.61% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paul Stuka also recently made the following trade(s):

• On Friday, May 8th, Paul Stuka acquired 65,626 shares of InspireMD stock. The stock was purchased at an average cost of $1.16 per share, with a total value of $76,126.16.
• On Thursday, May 7th, Paul Stuka acquired 6,378 shares of InspireMD stock. The stock was purchased at an average cost of $1.15 per share, with a total value of $7,334.70.
• On Wednesday, May 6th, Paul Stuka acquired 1,517 shares of InspireMD stock. The stock was purchased at an average cost of $1.12 per share, with a total value of $1,699.04.

InspireMD Price Performance

NYSE:NSPR opened at $1.17 on Thursday. The firm has a 50 day simple moving average of $1.46 and a 200-day simple moving average of $1.72. The firm has a market cap of $54.80 million, a PE ratio of -1.56 and a beta of 0.82. InspireMD, Inc. has a 1-year low of $1.02 and a 1-year high of $2.93.

Hedge Funds Weigh In On InspireMD

Several institutional investors and hedge funds have recently bought and sold shares of NSPR. Creative Planning acquired a new position in InspireMD during the second quarter worth approximately $44,000. Raymond James Financial Inc. increased its position in InspireMD by 28.9% during the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after purchasing an additional 10,000 shares during the last quarter. Rosalind Advisors Inc. increased its position in InspireMD by 0.6% during the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock worth $5,196,000 after purchasing an additional 14,109 shares during the last quarter. Soleus Capital Management L.P. increased its position in InspireMD by 99.5% during the second quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock worth $4,282,000 after purchasing an additional 940,831 shares during the last quarter. Finally, Courier Capital LLC increased its position in InspireMD by 83.3% during the third quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock worth $133,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 44.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on NSPR. Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Loop Capital set a $5.00 price target on shares of InspireMD in a research report on Tuesday, February 24th. Lake Street Capital set a $4.00 price target on shares of InspireMD in a research report on Monday, May 4th. Finally, Maxim Group initiated coverage on shares of InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.